Preparation and characterization of polymeric nanoparticles loaded with the flavonoid luteolin, by using factorial design
Keywords:
Luteolin, polymeric nanoparticles, characterization, factorial design, release kineticsAbstract
Nanoparticles containing luteolin flavonoid were prepared by using interfacial polymer deposition following solvent displacement. The formulation was optimized using factorial design. The parameters studied were the type of polymer [poly(ε-caprolactone) and poly(lactic-co-glycolic acid)], nature oil (isodecyl oleate and oleic acid) and the quantity of luteolin. Nanocapsules and nanospheres were also prepared and evaluated. Colloidal suspensions were characterized by evaluating pH, the particle size, the zeta potential, the morphological aspect and the kinetic release. A new High Performance Liquid Chromatography method was developed and validated in order to quantify luteolin in colloidal suspension allowing the analyses of the absolute recovery, entrapment efficiency and the kinetic release. The luteolin-absolute recovery ranged from 61.6% to 95%; entrapment efficiency was nearly 100% in all formulations and the particle sizes were smaller than 185.5 nm. The nanoparticles prepared with isodecyl oleate show a negative zeta potential. On the other hand, when oleic acid was utilized, the zeta potential was positive. The nanoparticles prepared by using isodecyl oleate have a more perfect spherical shape with a regular surface and form, homogeneity, and lower size dispersion. Nanocapsules and nanospheres have a similar release mechanism of pure diffusion according with Korsmeyer-Peppas’s model.
References
Frishman WH, MD, Beravol P, Carosella C. Alternative and complementary medicine for preventing and treating cardiovascular disease. Dis Mon. 2009; 55:121-192.
Capasso R, Izzo AA, Pinto L, Bifulco T, Vitobello C, Mascolo N. Phytotherapy and quality of herbal medicines. Fitoterapia. 2000; 71: S58-S65.
Zhang J, Wider B, Shang H, Li X, Ernst E. Quality of herbal medicines: challenges and solutions. Complement Ther Med. 2011; doi:10.1016/j.ctim.2011.09.004.
Del Rio JA, Fuster MD, Gomez P, Porras I, Garcia-Lidon A, Ortuno A. Citrus limon: a source of flavonoids of pharmaceutical interest. Food Chemistry 2004; 84: 457-461.
Havsteen B. The biochemistry and medical significance of the flavonoids. Pharmacol Ther. 2002; 96: 67-202.
Lopez-Lazaro M. Distribution and biological activities of the flavonoid luteolin. Mini Rev Med Chem. 2009; 9:31-59.
Choi C, Jung H, Kang S, Choi J. Antioxidant constituents and a new triterpenoid glycoside from Flos Lonicerae. Arch Pharm Res 2007; 30:1-7.
Miyazawa M, Hisama M. Antimutagenic activity of flavonoids from Chrysanthemum morifolium. Biosci Biotechnol Biochem 2003; 67:2091-2099.
Lin Y, Shi RX, Wang X, Shen HM. Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr Cancer Drug Targets. 2008; 8: 634-646
Bell LN. Stability testing of nutraceuticals and functional foods. In: Wildman REC, editor. Handbook of nutraceuticals and functional foods. New York, USA: CRC Press.; 2001. p. 501-516.
Fessi H, Puisieux F, Devissaguet J-P, Ammoury N, Benita S. Nanocapsule formulation by interfacial polymer deposition following solvent displacement. Int J Pharm. 1989; 55: R1–R4.
Reis CP, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine: Nanotech Biol Med. 2006; 2: 53–65.
Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloid Surfaces B. 2010; 75: 1–18.
Ajazuddin, Saraf S. Applications of novel drug delivery system for herbal formulations. Fitoterapia. 2010; 81: 680-689.
Kanno S, Tomizawa A, Ohtake T, Koiwai K, Ujibe M, Ishikawa M. Naringenin-induced apoptosis via activation of NF-kappaB and necrosis involving the loss of ATP in human promyeloleukemia HL-60 cells. Toxicol Lett. 2006; 166:131-139.
Ratnam DV, Ankola DD, Bhardwaj V, Sahana DK, Kumar MN. Role of antioxidants in prophylaxis and therapy: A pharmaceutical perspective. J Control Release. 2006; 113:189-207.
Krishnakumar N, Sulfikkarali N, Prasad NR, Karthikeyan S. Enhanced anticancer activity of naringenin-loaded nanoparticles in human cervical (HeLa) cancer cells. In: Biomedicine and preventive nutrition, V.1(4). Elsevier Masson SAS; 2011. p. 223-231.
Das S, Mandal AK, Ghosh A, Panda S, Das N, Sarkar S. Nanoparticulated quercetin in combating age related cerebral oxidative injury. Curr Aging Sci. 2008; 1:169-174.
Gao Y, Gu W, Chen L, Xu Z, Li Y. The role of daidzein-loaded sterically stabilized solid lipid nanoparticles in therapy for cardio-cerebrovascular diseases. Biomaterials. 2008; 29: 4129-4136.
Dube A, Nicolazzo JA, Larson I. Chitosan nanoparticles enhance the plasma exposure of (-)-epigallocatechin gallate in mice through an enhancement in intestinal stability. Eur J Pharm Sci. 2011; 44:422-426.
ICH [International Conference on Harmonization, FDA, USA]. Q2B: Validation of analytical procedures: methodology. 1996 (Available under: http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073384.pdf).
Levy MY, Benita S. Drug release from submicronized o/w emulsion: a new in vitro kinetic evaluation model. Int J Pharm. 1990; 66: 29–37.
Schaffazick SR, Pohlmann AR, Mezzalira G, Guterres SS. Development of nanocapsule suspensions and nanocapsule spray-dried powders containing melatonin. J Braz Chem Soc. 2006; 17: 562-569.
Kim H, Kim H-W, Jung S. Aqueous solubility enhancement of some flavones by complexation with cyclodextrins. Bull Korean Chem Soc. 2008; 29: 590-594.
Santos KC, Da Silva, MFGF, Fernandes JB, Vieira PC, Polikarpov I, Zucolotto V, Forim MR. Development and validation of a fast RP-HPLC method to determine the analogue of the thyroid hormone, 3,5,30-triiodothyroacetic acid (TRIAC), in polymeric nanoparticles. Anal Methods. 2011; 3: 1936-1942.
Govender T, Stolnik S, Garnett, MC, Illum L, Davis SS. PLGA nanoprticles prepared by nanopreciptation: drug loading and release studies of a water soluble drug. J Control Release. 1999; 57: 171-185.
Wei XW, Gong CY, Gou M, Fu SZ, Guo Q, Shi S, Luo F, Guo G, Qiu LY, Qian ZY. Biodegradable poly(epsilon-caprolactone)-poly(ethylene glycol) copolymers as drug delivery system. Int J Pharm. 2009; 1: 1-18.
Lacerda SP, Cerize NNP, Ré MI. Preparation and characterization of carnauba wax nanostructured lipid carriers containing benzophenone-3. Int J Cosmetic Science. 2011; 33: 312–321.
Bouchemal K, Briançon S, Perrier E, Fessi H. Nano-emulsion formulation using spontaneous emulsification: solvent, oil and surfactant optmisation. Int J Pharm. 2004; 280: 241-251.
Hackley VA, Clogston JD. Measuring the hydrodynamic size of nanoparticles in aqueous media using batch-mode dynamic light scattering. In.: McNeil SE, editor. Characterization of nanoparticles intended for drug delivery. New York: Humana Press. 2011. p.35-52.
De Melo NFS, Grillo R, Rosa AH, Fraceto LF, Dias-Filho NL, De Paula E, Araújo, DR. Desenvolvimento e caracterização de nanocápsulas de poli(L-lactídeo) contendo benzocaína. Quim Nova. 2010; 33: 65–69.
Wu L, Zhang J, Watanabe W. Physical and chemical stability of drug nanoparticles. Adv Drug Deliv Rev. 2011; 63: 456-469.
Clogston JD, Patri AK. Zeta Potential Measurement. In.: McNeil SE, editor. Characterization of nanoparticles intended for drug delivery. New York: Humana Press. 2011. p.63-70.
Teixeira M, Alonso MJ, Pinto MMM, Barbosa CM. Development and characterization of PLGA nanospheres and nanocapsules containg xanthone and 3-methoxyxanthone. Eur J Pharm. Biopharm. 2005; 59: 491–500.
Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Int. J. Pharm. 1983; 15, 25.
